Old and new antibiotics for therapy of multidrug resistant bacteria.

July 2, 2017 at 9:33 pm

Rev Esp Quimioter. Sept 2016 V.29 Suppl 1 P.39-42.

[Article in Spanish]

Pintado V1.

Author information

1 Vicente Pintado, Servicio de Enfermedades Infecciosas. Hospital Ramón y Cajal. Madrid, Spain. vicente.pintado@salud.madrid.org

Abstract

The lack of new antibiotics for multidrug-resistant bacteria is a matter of concern in microorganisms such as Pseudomonas aeruginosa, ESBL- and carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii, methicillin-resistant Staphylococcous aureus and vancomycin-resistant Enterococcus faecium.

This situation has conditioned the reuse of “old” antibiotics (colistin, fosfomycin), the use of more recent antibiotics with new indications or dosage regimens (tigecycline, meropenem) and the introduction of “new” antibiotics (β-lactams, lipoglycopeptides, oxazolidinones) that are the subject of this review.

PDF

http://seq.es/seq/0214-3429/29/sup1/9pintado.pdf

Advertisements

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Epidemiología, Infecciones emergentes, Metodos diagnosticos, REPORTS, Resistencia bacteriana, Sepsis, Update.

The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Pyogenic vertebral osteomyelitis: identification of microorganism and laboratory markers used to predict clinical outcome.


Calendar

July 2017
M T W T F S S
« Jun   Aug »
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Most Recent Posts


%d bloggers like this: